Why the study?
Growing secular trends in diabetes mellitus and heart failure prevalence forecast an increasing disease burden, underscoring the need for effective therapeutic strategies.
This AHA/HFSA scientific statement outlines the shared pathophysiology and comprehensive management strategies for patients with type 2 diabetes and heart failure.
Integrates care for type 2 diabetes and heart failure to optimize outcomes; extends prior guidelines with unified synergistic strategies.
Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.
No takes yet. Share an insight, caveat, or question.
Dunlay et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Heart failureMore from Circulation